Payment overview · 2025
General Payments
$203.58
12 reported records · 6 companies
Healthcare provider profile · identity verified
Regina M Dorman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TALLMADGE, OH · NPI 1699765404
Verified facts
What the public records show
CMS Open Payments records show Regina M Dorman, M.D. received $203.58 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.22 | 36.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.01 | 23.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.22 | 14.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.00 | 12.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.56 | 7.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.57 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.58 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.19 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 115 |
| Losartan Potassium | Losartan Potassium | 383 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 82 |
| Omeprazole | Omeprazole | 209 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 62 |
| Lisinopril | Lisinopril | 179 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 35 |
| Sertraline Hcl | Sertraline Hcl | 123 | 37 |
| Furosemide | Furosemide | 116 | 39 |
| Ezetimibe | Ezetimibe | 114 | 30 |
| Lovastatin | Lovastatin | 103 | 28 |
| Gabapentin | Gabapentin | 102 | 41 |
| Eliquis | Apixaban | 99 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 27 |
| Simvastatin | Simvastatin | 93 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 26 |
| Metformin Hcl Er | Metformin Hcl | 87 | 24 |
| Alendronate Sodium | Alendronate Sodium | 84 | 20 |
| Metformin Hcl | Metformin Hcl | 81 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 21 |
| Allopurinol | Allopurinol | 69 | 18 |
| Mirtazapine | Mirtazapine | 69 | 19 |
| Potassium Chloride | Potassium Chloride | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 65 | 21 |
| Glimepiride | Glimepiride | 63 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Trazodone Hcl | Trazodone Hcl | 60 | 22 |
| Synthroid | Levothyroxine Sodium | 59 | 21 |
| Alprazolam | Alprazolam | 55 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 20 |
| Meloxicam | Meloxicam | 54 | 21 |
| Pregabalin | Pregabalin | 54 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 18 |
| Lorazepam | Lorazepam | 53 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 50 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 14 |
| Bupropion Xl | Bupropion Hcl | 48 | 20 |
| Carvedilol | Carvedilol | 47 | 14 |
| Ozempic | Semaglutide | 45 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 14 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 12 |
| Prednisone | Prednisone | 37 | 25 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 12 |
| Famotidine | Famotidine | 33 | 12 |
| Cephalexin | Cephalexin | 32 | 29 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Prolia | Denosumab | 23 | 16 |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Linzess | Linaclotide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Eucrisa | Crisaborole | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.58 · 12 records | ABBVIE INC. | AREXVY, BEXSERO, EVENITY, INSPIRE, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error